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Glaucoma is the leading cause of irreversible blind-
ness and the second most common cause of blindness 
after cataract [1]. The main characteristic of glaucoma is a 
specific optic neuropathy with reduced number of retinal 
ganglion cells accompanied by characteristic progressive 
constriction of the visual field [2,3]. Although increased 
intraocular pressure (IOP) has been considered as a major 
risk factor for glaucoma [4], there are other concomitant 
factors affecting the eye such as glutamate excitotoxicity 
[5], reduced ocular blood flow [6-9], vascular dysregulation 
[10,11], and reactive oxygen species-related oxidative dam-
age that have been suggested as important etiologic factors 
in glaucoma pathogenesis [12,13]. The trabecular mesh-
work, optic nerve, and retinal ganglion cells are known as 
the major targets of oxidative damage in the pathological 
development of glaucoma [14-21].
Why is oxidative stress so important in ocular disease? 
Eyes are continually exposed to light in order to collect 
data from the outer environment, and thus reactive oxygen 
species are being produced by ionizing or non-ionizing ra-
diation when the eyes are open [22]. Reactive oxygen spe-
cies are also produced by aerobic metabolism. Even when 
the eye is in darkness, the retina consumes more oxygen 
than when it is in light [23]. Ischemia and reperfusion in-
jury caused by ocular vascular dysregulation also induce 
oxidative damage [24,25]. Against this vulnerability to oxi-
dative damage, the eye has its own protective mechanism 
of high levels of both ascorbic acid and glutathione (GSH) 
[26-32]. Other protective systems including enzymatic 
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Purpose: Oxidative stress plays a critical role in the pathogenesis of glaucoma. Glutathione is a major antioxi-
dant molecule present in intracellular or extracellular space. Herein, we aimed to examine circulating glutathi-
one level in normal tension glaucoma (NTG), which comprises the largest proportion of glaucoma disease in 
the Korean population.
Methods: Nineteen NTG patients (NTG group) and 30 age- and gender-matched normal control subjects (control 
group) were included. Antecubital venous puncture was performed between 8 and 10 o’clock in the morning to 
obtain a 4 mL venous blood sample. Total glutathione level was measured by the spectrophotometric method 
at 412 nm. Correlation of total glutathione level with mean deviation and pattern standard deviation from the 
Humphrey visual field test was analyzed in the NTG group. 
Results: Total glutathione level in circulating blood was 524.02 ± 231.09 nmol and 586.06 ± 156.08 nmol in the 
NTG group and the control group, respectively. The difference between these values was not statistically 
significant (p = 0.121, F = 2.212). Age had no significant effect on circulating total glutathione level in either the 
NTG group (p = 0.171, r = -0.328) or the control group (p = 0.380, r = -0.166). In the NTG group, circulating total 
glutathione level had no significant relationship with mean deviation (p = 0.226, F = 1.636) and pattern stan-
dard deviation (p = 0.200, F = 1.766) after correcting for age and gender.
Conclusions: In NTG patients, circulating total glutathione levels were not different compared to those of normal 
subjects. 
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(superoxide dismutase, GSH peroxidase, and catalase) and 
non-enzymatic antioxidants (cysteines, tocopherols, and 
retinols) are present in the eye [19]. Under normal physi-
ologic conditions, there is a state of equilibrium between 
the endogenous production of free radicals and their neu-
tralization by antioxidant defense mechanisms. If these 
protective systems fail, damage to the ocular tissues can 
occur, and various diseases can develop such as cataract 
[33], age-related macular degeneration [34], and glaucoma 
[35].
GSH is a major non-enzymatic antioxidant present in 
both intracellular and extracellular spaces [36,37]. The 
GSH redox system protects ocular tissues from the damage 
induced by low H2O2 concentrations through direct and 
indirect mechanisms [38,39]. A considerable amount of 
evidence suggests GSH depletion as an important risk fac-
tor for glaucoma. In the aqueous humor of primary open 
angle glaucoma (POAG) patients, activity of antioxidant 
enzymes, including glutathione peroxidase, is increased 
and total antioxidant potential is decreased, suggesting that 
chronic oxidative damage occurs in outflow pathways [40]. 
An increase in serum autoantibody against glutathione-
S-transferase has been reported in glaucoma patients [41]. 
Genetic polymorphisms have been detected for GSH trans-
ferase isoenzyme, and the GSTM1-null genotype has been 
found to be significantly common in patients with primary 
open-angle glaucoma compared to controls [42]. Patients 
with POAG exhibit low levels of circulating glutathione 
[43]. In an in vivo study, a mouse retina with systemic GSH 
reduction showed increased retinal neuronal apoptosis [44] 
and altered expressions of bcl-2 family mRNA and heat 
shock protein mRNA [45], suggesting subsequent retinal 
neuronal protective mechanisms may be changed by sys-
temic GSH depletion. 
Normal tension glaucoma (NTG) is the most common 
type of glaucoma in Korea and Japan [46-48]. This is 
unique in comparison with Western populations. The prev-
alence of NTG is about 3.5-fold higher than that of POAG 
with increased IOP in Korea (The Namil Study, the Kore-
an Glaucoma Society) [48]. However, the pathophysiologic 
mechanism of NTG is little known. Vascular dysregula-
tion in the optic nerve head and some influence of high 
normal intraocular pressure are known as mild risk factors 
[10,11,49]. Although IOP is still the major target of treat-
ment for NTG in current practice [50], attention is shifting 
to other modalities such as neuroprotection, improvement 
of ocular blood flow, and antioxidant supplementation [51]. 
Moreover, some patients with POAG are also facing these 
new forms of therapy due to the progression of optic neu-
ropathy despite well-controlled IOP [52] due to the multi-
factorial etiology of glaucoma. 
Therefore, information about the status of systemic GSH 
level in NTG will help to elucidate the role of oxidative 
stress in the disease progression of NTG. The purpose of 
this study was to determine the status of circulating total 
GSH levels in patients with normal tension glaucoma and 
to compare levels with those of people without glaucoma.
Materials and Methods
Study sample 
Patients with NTG attending the glaucoma clinic of the 
Catholic Eye Center at St. Mary’s Hospital (Seoul, Korea) 
between June 2008 and October 2008 were considered for 
inclusion in this prospective study. Ethical approval was 
obtained from the committee of St. Mary’s Hospital insti-
tutional review board, and written informed consent was 
received from all subjects before entry into the study. 
Patients were diagnosed as having NTG if IOP measure-
ments were less than 22 mmHg by Goldmann applanation 
tonometry, characteristic glaucomatous cupping of the op-
tic disc was observed on funduscopic examination, normal 
open anterior chamber angles was seen on gonioscopy, and 
repeatable visual field defects consistent with the diagnosis 
of glaucoma were observed in the results obtained with 
program 24-2 of the Humphrey field analyzer (Carl Zeiss 
Meditec, Dublin, CA, USA). The study’s ocular exclusion 
criteria included any IOP measurement greater than 21 
mmHg, narrow iridocorneal angles, evidence of secondary 
open-angle glaucoma, history of previous intraocular sur-
gery, and other nonglaucomatous ocular diseases including 
cataract, diabetic retinopathy (DR) and age-related macu-
lar degeneration (ARMD). The control group was recruited 
from a group of age- and gender-matched volunteers and 
was composed of subjects who had never had glaucoma or 
other ocular diseases such as cataract, DR, or ARMD. 
Other exclusion criteria for both groups were smoking 
and a history of any chronic systemic disease with pre-
sumed low GSH level, including autoimmune diseases, 
alcoholic liver disease, cancer, and diabetes mellitus. After 
this selection, the experimental group was narrowed to 19 
patients with NTG, and that control group contained 30 
subjects. 
Blood sampling
Subjects were instructed to fast from midnight to 8 
a.m. on the morning of the test. All blood samples were 
obtained by a qualified registered nurse in the morning, 
between 8 and 10 a.m. Four milliliters of blood were col-
lected in EDTA-treated tubes (to prevent oxidation) by 
venipuncture to the antecubital vein. One thousand micro-
liters of blood was then transferred into a centrifuge tube 
for initial processing. Red blood cells (RBC) were sepa-
rated from plasma by centrifugation at 600 ×g for 10 min-
utes. The pellet RBCs were then transferred into another 
microcentrifuge tube and washed twice with 3 volumes of 86
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phosphate buffered saline (pH = 7.4). A 200 microliter ali-
quot of RBC pellets was placed in another microcentrifuge 
tube, to which 200 microliters of 5% 5-sulfosalicylic acid 
(SSA) were added and then incubated for 10 minutes at 
4˚C. After centrifugation at 10,000 ×g for 10 minutes, 100 
microliters of the supernatant were immediately cooled at 
-70˚C. All of these procedures were performed within 2 
hours from the time of blood collection. The next steps of 
the GSH analysis were performed within 10 days. 
Glutathione analysis
Total GSH levels were assessed by the 5, 5’-dithiobis-(2-
nitrobenzoic acid) recycling procedure, as described in a 
previous study [52]. The glutathione assay kit from Sigma 
(Glutathione assay kit, product code CS0260; St Louis, 
MO, USA) was used.
A standard curve from 3.125 to 50 nanomoles in double-
fold increments using a GSH standard solution was pre-
pared for each 96-well plate. The standards contained the 
same final concentrations of SSA as used for the samples. 
To each well of a 96-well plate, 150 microliters of working 
buffer and 10 microliters of standard or sample were added 
in duplicate, and the plate was incubated at room tempera-
ture for 5 minutes. Finally, 50 microliters of 0.16 mg/mL 
nicotinamide adenine dinucleotide phosphate (NADPH) 
was added, and the plate was read at 412 nm using a 96-
well plate reader. A standard curve was then generated by 
linear regression.
Statistical analysis 
The statistical analysis was performed on a computer 
equipped with SPSS ver. 12 (SPSS Inc., Chicago, IL, USA). 
Data are expressed as the mean ± standard deviation. Dif-
ferences between groups at baseline for age, mean devia-
tion (MD) and pattern standard deviation (PSD) were cal-
culated using Student’s t-test. Difference between groups 
at baseline for gender was calculated using the χ
2-test 
(Fisher’s exact test). Differences between the two study 
groups in blood GSH level were computed by analysis of 
covariance using age as a cofactor. Differences between 
males and females in blood GSH level were computed by 
Student’s t-test for each study group. A correlation was 
performed to determine the association of age and blood 
GSH level. A multiple regression was performed to test the 
influences of age, gender, and blood GSH level on MD and 
PSD from the 24-2 test pattern of the Humphrey field ana-
lyzer. Results with p = 0.05 were considered statistically 
significant. 
The minimum sample size needed was calculated from 
the formula [(u + v)(σ
12 + σ
22) / (μ1 - μ2)
2] with 90% power 
and a 5% level of significance. The sample size needed was 




2) / (300 - 200)
2] using the reported data [44].
Results
Nineteen patients with NTG and 30 normal control sub-
jects were included in this study. The demographics of the 
study groups are described in Table 1. There was no signif-
icant difference in age (p = 0.056) or gender (p = 0.337, χ
2 
= 0.921) distribution between the NTG group and control 
group. There were significant differences in MD (p = 0.000) 
and PSD (p = 0.000) between the two groups. 
Total glutathione level in circulating blood was 524.02 ± 
Table 1. Patient demographics (mean ± SD) 
Control NTG p-value
No. of patients 30 19
Age (yr)   52.70 ± 6.70   56.26 ± 8.48 0.056
Sex (male : female) 20 : 10 10 : 9 0.377
MD   -0.75 ± 1.24   -5.66 ± 4.32 0.000
PSD   1.58 ± 0.94   5.06 ± 4.03 0.000
Statistical analysis was performed with Student’s t-test (age, MD, and PSD) and Fisher’s exact test (sex).



































Fig. 1. Median and interquartile range values of total circulating 
glutathione (GSH) level in the control group and normal tension 
glaucoma (NTG) group. Total GSH levels were not statistically 
different between the two groups (p = 0.121, F = 2.212).87
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231.09 nmol and 586.06 ± 156.08 nmol in the NTG group 
and the control group, respectively. Circulating total GSH 
levels were not statistically different between the NTG 
group and control group (p = 0.121, F = 2.212) (Fig. 1). In 
the NTG group, the mean glutathione level was 589.41 
± 239.64 nmol in males and 451.35 ± 210.39 nmol in fe-
males. In the control group, the mean glutathione level was 
618.98 ±208.16 nmol in males and 569.61 ± 125.70 nmol 
in females. There was no statistically significant differ-
ence in total GSH level between males and females in the 
NTG group (p = 0.424) (Fig. 2) or in the control group (p 
= 0.202) (Fig. 3). There was no significant assotciation be-
tween age and total GSH level in the NTG group (p = 0.171, 
r = -0.328) (Fig. 4) or in the normal group (p = 0.380, r = 
-0.166) (Fig. 5). In the NTG group, after correcting for age 
and gender influences on systemic total GSH level, there 
was no significant association between GSH level and vi-
sual field parameter (MD: p = 0.226, R
2 = 0.260; PSD: p = 
0.200, R
2 = 0.275) (Figs. 6 and 7).
Discussion
Glutathione is normally present in the cornea, lens, tra-



































Fig. 5. Correlation between total glutathione (GSH) level and 
age in the control group. There was no significant association be-
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Fig. 2. Median and interquartilic range values of total glutathione 
(GSH) level in the normal tension glaucoma (NTG) group; com-
parison between male and female patients. There was no signifi-
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Fig. 4. Correlation between total glutathione (GSH) level and age 
in year in the normal tension glaucoma group. There was no sig-
nificant association between total GSH level and age (r = -0.328, 
p = 0.171).
Fig. 3. Median and interquartilic range values of total glutathione 
(GSH) level in the control group; comparison between male and 
female patients. There was no significant difference between 
males and females (p = 0.202) in total circulating GSH level.88
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glutathione and related enzyme activity in the lens, cornea, 
retina, and other eye tissues occur with aging, cataract, 
diabetes, irradiation, and administration of some drugs. 
Many ocular diseases including keratoconus, cataract, 
glaucoma, diabetic retinopathy, and age-related macular 
degeneration may occur by oxidative damage induced by 
an abnormal glutathione redox state.
In terms of glaucoma, the major interest lies on two 
specific structures, the trabecular meshwork and retina, 
because the trabecular meshwork is a rate-limiting struc-
ture of aqueous outflow pathway controlling intraocular 
pressure, and the retina is one of the target structures of 
glaucomatous optic neuropathy. 
Studies on the calf trabecular meshwork (TM) have 
shown the presence of glutathione, glutathione reductase, 
and glucose-6-phosphate dehydrogenase, indicating that 
the TM is well supplied with the capacity to generate and 
use NADPH to maintain GSH. It has been supposed that 
GSH is able to protect the TM against H2O2-induced oxi-
dative damage, which would decrease the aqueous humor 
outflow [19]. Altered GSH and GSH activities have also 
been reported in the trabecular meshwork and aqueous 
humor of patients with glaucoma [40,41,53-56]. All of these 
results imply that reduced activity of GSH in the TM may 
influence aqueous outflow facility and thus elevate IOP. 
Additional studies of the role of glutathione in glau-
coma pathogenesis are related to studies of the trabecular 
meshwork. However, the retina is a major target organ 
in glaucoma pathogenesis, and glutathione also exists 
in the retina. Therefore, abnormal glutathione function 
within the retina may play an important role in glaucoma. 
Although the function of glutathione in the retina is not 
fully understood, there is some evidence that it may have 
a role in neuroprotection under harmful conditions such as 
ischemia and oxidative damage. In the retina, glutathione 
is predominately localized to Muller cells and horizontal 
cells. According to a study by Schutte and Werner [57], us-
ing immunocytochemical methods for glutathione, post-
mortem ischemic injury longer than 10 minutes resulted in 
strong labeling of neurons, particularly of retinal ganglion 
cells, whereas Muller cells were essentially devoid of im-
munoreactivity. This means that glutathione molecules 
were transferred from Muller cells to retinal ganglion cells 
to protect ganglion cells from ischemic injury. In a study 
by Carter-Dawson et al. [58], Muller cells in glaucomatous 
monkey retinas showed significantly greater immunoreac-
tivity for glutathione than control retinas, increasing with 
the duration of elevated intraocular pressure. 
According to our previous study, a 15% reduction of to-
tal retinal GSH level by intraperitoneal injection of buthio-
nine sulfoximine caused retinal neuronal apoptosis in mice 
[44]. To reach this level of GSH in the retina, circulating 
total GSH might need to be lowered even further. In the 
same mouse, total GSH level in the heart was reduced to 
60% of that of the control mouse (unpublished data). We 
hypothesized that systemic total glutathione level might 
be changed in NTG patients in whom there may be ad-
ditional factors other than increased IOP for glaucomatous 
damage. If there is little influence of IOP on glaucomatous 
optic neuropathy in NTG pathogenesis, and if oxidative 
damage is one of the major risk factors for NTG, the anti-
oxidant capacity of GSH might have been changed in NTG 
patients. However, as the results of this study show, there 
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Fig. 7. Correlation between total glutathione (GSH) level and 
pattern standard deviation (PSD) in the normal tension glaucoma 
group. After correcting for age and gender influence, there was 
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Fig. 6. Correlation between total glutathione (GSH) level and 
mean deviation (MD) in the normal tension glaucoma group. 
After correcting for age and gender influence, there was no sig-
nificant association between GSH level and MD (p = 0.226, R
2 = 
0.260).89
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NTG group and control group. This difference in results 
between human and animal subjects is possibly due to the 
difference in background factors such as genetic homoge-
neity and diet.
Systemic glutathione level can change within a day and 
is affected by diet and medications. We obtained blood 
samples at a fixed time (8 a.m.) after fasting, as in the pre-
vious report [43], in order to reduce the sampling bias. 
Gherghel et al. [43] demonstrated that patients with 
POAG exhibit low levels of circulating glutathione, sug-
gesting a general compromise of the antioxidative defense. 
In Gherghel’s study, total GSH level in the POAG group 
was about 75% (225.27 ± 83.03) of that of the control group 
(332.23 ± 98.50). In addition to the IOP range, there is one 
more thing we should consider about the difference in 
results between Gherghel’s study and ours. In contrast to 
Caucasians, Korean and Japanese people have a higher 
prevalence of NTG than POAG with a 3.5-fold elevation 
in pressure. In Choe and Hong [46]’s study of Koreans, the 
estimated prevalence of POAG in the population over 20 
years of age was 2.04%, and the prevalence of NTG was 
1.71% (83.8% of POAG). In Iwase et al. [47]’s study of Japa-
nese individuals, the estimated prevalence of POAG in the 
population older than 40 years of age was 3.9%, and the 
prevalence of cases of POAG with IOP levels of 21 mmHg 
or less was 3.6% (92.3% of POAG). Korean and Japanese 
people might have different risk factors compared to Cau-
casian populations. Different racial characteristics may 
lead to different results. These issues illustrate the impor-
tance of further studies of POAG with elevated IOP in Ko-
rea because of the absence of data on systemic glutathione 
levels in Korean POAG patients. 
Although there were no statistically significant differ-
ences in total GSH level between the two groups in this 
study, the range of total GSH level in the NTG group 
showed a wider distribution compared to that of the con-
trol group. The proportions of patients with very low 
total GSH level and with very high total GSH level were 
larger in the NTG group. Considering the smaller sample 
size of the NTG group, this characteristic might be more 
meaningful. From this point of view, we can also hypoth-
esize that the homeostasis of systemic glutathione-related 
antioxidant capacity may be inadequately controlled in 
the NTG patient. Both a low level and a high level of total 
GSH may be related to insufficient anti-oxidant activity 
against reactive oxygen species.
It is known that blood GSH level is influenced by gen-
der, with men demonstrating higher levels than women. 
Our results found that mean total GSH level was slightly 
higher in men then in women (NTG group, 589.41 ± 239.64 
nmol in males and 451.35 ± 210.39 nmol in females; control 
group, 618.98 ± 208.16 nmol in males and 569.61 ± 125.70 
nmol in females), but there were no significant differences 
in blood GSH level between men and women in either the 
NTG group (p = 0.424) or the control group (p = 0.202). 
This might be due to either the small sample size or racial 
characteristics. There are few data on normal circulating 
GSH levels in the Korean population [59,60]. Further popu-
lation-based studies are needed to fully explain the results 
of this study.
Age is known as one of the influencing factors on sys-
temic GSH level. It has been reported that about half of 
healthy elderly people show low blood GSH level. A nega-
tive correlation between age and blood GSH level has also 
been reported. Our results demonstrated a slightly decreas-
ing trend of GSH level as age increases but found no sig-
nificant correlation between age and total circulating GSH 
level in either the NTG group or control group. This might 
be also due to the small sample size. 
We also expected that if the systemic total GSH level is 
related to the range of glaucomatous optic neuropathy, then 
the extent of visual field damage in NTG patients might 
be proportional to the decrement of total GSH level. But 
the results of this study also showed no significant relation 
between the MD and PSD of the visual field test and total 
GSH level. We think this might be due to the finding of no 
significant difference in total GSH level. Since there was 
no difference of total GSH level between the NTG group 
and normal subject group, the extent of visual function 
may not have been influenced by GSH level. Another pos-
sibility is that there might be a change in circulating GSH 
only in patients with fast progression of optic nerve dam-
age. If we had had a greater number of patients, we could 
have divided patients into two groups with progressing and 
non-progressing optic nerve damage and compared them. 
However, because normal tension glaucoma is a slowly 
progressing disease in most patients, this would require 
enormous time and effort to recruit a sufficient number of 
volunteers with progressive disease. 
A major concern of this study is that the study results 
came from only one measurement of serum glutathione 
level. Therefore, these results might not be able to represent 
the long-term status of patients. However, because there 
are few reports about the relationship between normal 
tension glaucoma and glutathione, this study represents a 
meaningful step toward understanding the pathophysiol-
ogy of normal tension glaucoma.
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